The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 25 | 40.4x | 20.1x | Below average | |
Growth | 73 | 47.4% | 5.6% | Above average | |
Quality | 74 | 54.0% | 7.6% | Above average | |
Safety | 69 | 1.0x | 0.4x | Above average | |
Capital Return | 24 | 0.54% | 2.19% | Below average | |
Momentum | 66 | — | — | Near average | |
Sentiment | 50 | — | — | Near average |
Eli Lilly and Company is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Eli Lilly and Company shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.

AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Analyst reviews for Eli Lilly stock showed remarkable stability in expectations over the last week, with a slight positive bias on a monthly basis as the average price target rose by 0.61%. The convergence between the median price target (1270) and the arithmetic mean (1266.17) reflects a state of strong consensus among the 11 analysts covering the stock, with a positive price gap compared to the current price of 1083.23.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.